Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

Regeneron Pharmaceuticals / Equity Bottom-Up

<ul><li>Regeneron Pharmaceuticals reported its third-quarter 2025 financial results, showcasing a mixed performance with both strong growth in some product lines and challenges in others.</li><li>The company's revenues reached $3.8 billion, marking a modest 1% increase from the previous year.</li><li>This growth was primarily driven by solid performances from several key products, including Dupixent, Libtayo, and EYLEA HD.</li></ul>

Regeneron Pharmaceuticals reported its third-quarter 2025 financial results, showcasing a mixed performance with both strong growth in some product lines and challenges in others.The company's revenues reached $3.8 billion, marking a modest 1% increase from the previous year.This growth was primarily driven by solid performances from several key products, including Dupixent, Libtayo, and EYLEA HD.

Regeneron Bets Big on U.S. Manufacturing – Can $7 Billion Transform Its Future?

<ul><li>Regeneron Pharmaceuticals presented a mixed performance for the second quarter of 2025, showcasing robust growth in certain product lines while facing challenges in others.</li><li>Overall, the company reported total revenues of $3.7 billion, marking a year-over-year increase of 4%, primarily buoyed by the impressive sales growth of flagship therapies like Dupixent and Libtayo, as well as the introduction and expansion of EYLEA HD.</li><li>However, the legacy EYLEA product witnessed a significant decline, with U.S. sales dropping 39% from the previous year due to competitive pressures and ongoing shifts toward EYLEA HD.</li></ul>

Regeneron Pharmaceuticals presented a mixed performance for the second quarter of 2025, showcasing robust growth in certain product lines while facing challenges in others.Overall, the company reported total revenues of $3.7 billion, marking a year-over-year increase of 4%, primarily buoyed by the impressive sales growth of flagship therapies like Dupixent and Libtayo, as well as the introduction and expansion of EYLEA HD.However, the legacy EYLEA product witnessed a significant decline, with U.S. sales dropping 39% from the previous year due to competitive pressures and ongoing shifts toward EYLEA HD.

Regeneron Pharmaceuticals: An Insight Into EYLEA Revenue and Market Dynamics!

<ul><li>Regeneron Pharmaceuticals' first quarter 2025 results illustrate a multifaceted performance landscape, marked by both promising advancements and significant hurdles across its drug portfolio.</li><li>Starting with EYLEA, the company saw U.S. net sales of $736 million, a decrease of 39% compared to the prior year, amid heightened competition from low-cost, off-label Avastin, influenced by patient affordability issues due to a funding gap at co-pay assistance foundations.</li><li>While EYLEA HD sales increased by 54% year-over-year, its sequential growth was stagnant.</li></ul>

Regeneron Pharmaceuticals' first quarter 2025 results illustrate a multifaceted performance landscape, marked by both promising advancements and significant hurdles across its drug portfolio.Starting with EYLEA, the company saw U.S. net sales of $736 million, a decrease of 39% compared to the prior year, amid heightened competition from low-cost, off-label Avastin, influenced by patient affordability issues due to a funding gap at co-pay assistance foundations.While EYLEA HD sales increased by 54% year-over-year, its sequential growth was stagnant.

Regeneron Pharmaceuticals: An Insight Into Dupixent's Market Presence & Recent Oncology Portfolio Expansion!

<ul><li>Regeneron Pharmaceuticals presented its fourth-quarter 2024 results, revealing a 10% year-over-year revenue growth, driven by strong performances from key product lines such as Dupixent, EYLEA, and Libtayo.</li><li>Dupixent, in particular, has become a blockbuster treatment in multiple indications, showing robust uptake across the globe with more than 1 million patients currently benefiting from the drug in various approved applications.</li><li>However, the performance of EYLEA was noted in a competitive landscape, with the company focused on increasing the market share of EYLEA HD through upcoming product enhancements like prefilled syringe options and extended dosing intervals.</li></ul>

Regeneron Pharmaceuticals presented its fourth-quarter 2024 results, revealing a 10% year-over-year revenue growth, driven by strong performances from key product lines such as Dupixent, EYLEA, and Libtayo.Dupixent, in particular, has become a blockbuster treatment in multiple indications, showing robust uptake across the globe with more than 1 million patients currently benefiting from the drug in various approved applications.However, the performance of EYLEA was noted in a competitive landscape, with the company focused on increasing the market share of EYLEA HD through upcoming product enhancements like prefilled syringe options and extended dosing intervals.

Regeneron Pharmaceuticals: Libtayo Expansion To Up Their Oncology Game!

Equity Long-Short Analyst

Pyari Menon

Thematic (Sector/Industry)

<ul>
<li>Innovation data suggests that <a href="https://www.smartkarma.com/entities/bayer-ag" target="_blank" data-smartkarma-citation="entities:26881:1" rel="noopener">Bayer AG (BAYN GY)</a> has an almost monopoly stake in agriculture-related microbial, followed by <a href="https://www.smartkarma.com/entities/dupont-de-nemours-inc" target="_blank" data-smartkarma-citation="entities:9239:1" rel="noopener">DuPont (DD US)</a> </li>
<li>In non-ag microbial space <a href="https://www.smartkarma.com/entities/moderna-inc" target="_blank" data-smartkarma-citation="entities:28744:1" rel="noopener">Moderna Inc (MRNA US)</a>,  <a href="https://www.smartkarma.com/entities/codexis-inc" target="_blank" data-smartkarma-citation="entities:26400:1" rel="noopener">Codexis Inc (CDXS US)</a>,  <a href="https://www.smartkarma.com/entities/regeneron-pharmaceuticals" target="_blank" data-smartkarma-citation="entities:9167:1" rel="noopener">Regeneron Pharmaceuticals (REGN US),</a><a href="https://www.smartkarma.com/entities/immatics-nv" target="_blank" data-smartkarma-citation="entities:33092:1" rel="noopener">Immatics NV (IMTX US)</a> lead the field</li>
<li>In the nascent area of bacteriophages which could be a game-changer to fight against antibiotic-resistant bacteria BOEHRINGER INGELHEIM, <a href="https://www.smartkarma.com/entities/johnson-johnson" target="_blank" data-smartkarma-citation="entities:1132:1" rel="noopener">Johnson &amp; Johnson (JNJ US)</a>, and <a href="https://www.smartkarma.com/entities/pfizer-inc" target="_blank" data-smartkarma-citation="entities:1131:1" rel="noopener">Pfizer Inc (PFE US) </a>lead</li>
</ul>


Innovation data suggests that Bayer AG (BAYN GY) has an almost monopoly stake in agriculture-related microbial, followed by DuPont (DD US) 
In non-ag microbial space Moderna Inc (MRNA US),  Codexis Inc (CDXS US),  Regeneron Pharmaceuticals (REGN US),Immatics NV (IMTX US) lead the field
In the nascent area of bacteriophages which could be a game-changer to fight against antibiotic-resistant bacteria BOEHRINGER INGELHEIM, Johnson &amp; Johnson (JNJ US), and Pfizer Inc (PFE US) lead


Insights from Data Mining Technical Publications - Microbes - Bacteriophages

United States

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company. The Company discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions. Regeneron Pharmaceuticals serves the healthcare sector in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Regeneron Pharmaceuticals (REGN UW)

Regeneron Bets Big on U.S. Manufacturing – Can $7 Billion Transform Its Future?

Regeneron Pharmaceuticals reported its third-quarter 2025 financial results, showcasing a mixed performance with both strong growth in some...

Baptista Research

Regeneron Pharmaceuticals: An Insight Into EYLEA Revenue and Market Dynamics!

Regeneron Pharmaceuticals presented a mixed performance for the second quarter of 2025, showcasing robust growth in certain product lines while...

Baptista Research

Regeneron Pharmaceuticals: An Insight Into Dupixent's Market Presence & Recent Oncology Portfolio Expansion!

Regeneron Pharmaceuticals' first quarter 2025 results illustrate a multifaceted performance landscape, marked by both promising advancements and...

Baptista Research

Regeneron Pharmaceuticals: Libtayo Expansion To Up Their Oncology Game!

Regeneron Pharmaceuticals presented its fourth-quarter 2024 results, revealing a 10% year-over-year revenue growth, driven by strong performances...

Baptista Research

Insights from Data Mining Technical Publications - Microbes - Bacteriophages

Innovations are modifying and harnessing microbes for new uses in agriculture, industry, and as potential new therapeutics to replace or...

Pyari Menon

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)